Clinical Trial Update: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two doses of galantamine to placebo in Alzheimer's disease has completed, evaluating safety and effectiveness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Alzheimer Disease, Dementia | Phase 3 | Status: COMPLETED